Pacira BioSciences, Inc. (PCRX) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 36 analysts43.3% Below Target
PCRX trades 43.3% below Wall Street's consensus target of $32.00.
Current Price$22.33
Average Target$32.00
Low$32.00
Median$32.00
High$32.00
Analyst Target Range
Forward P/E7.8x
(Value)
PEG Ratio—
Implied Growth+1165.2%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PCRX achieves its forward estimates and maintains a stable P/E multiple of 7.8x. This scenario reflects the blended consensus of 36 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PCRX Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Pacira BioSciences, Inc. (PCRX) has a Wall Street consensus price target of $32.00, based on estimates from 36 covering analysts. With the stock currently trading at $22.33, this represents a potential upside of +43.3%. The company has a market capitalization of $878M.
Analyst price targets range from a low of $32.00 to a high of $32.00, representing a 0% spread in expectations. The median target of $32.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 15 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PCRX trades at a trailing P/E of 139.6x and forward P/E of 7.8x. Analysts expect EPS to grow +1165.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $29.47, with bear and bull scenarios of $18.57 and $38.83 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+63.9%
Industry Consensus
Avg Forward P/E
12.8x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRGOPerrigo Company plc | $1.4B | $10.25 | $36.20 | +253.2% | Hold | 4.8x | 36 |
 BHCBausch Health Companies Inc. | $1.8B | $4.77 | $8.00 | +67.7% | Buy | 1.1x | 38 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.38 | $60.00 | +35.2% | Buy | 17.8x | 14 |
 PAHCPhibro Animal Health Corporation | $1.3B | $31.85 | $49.00 | +53.8% | Buy | 10.4x | 14 |
 HALOHalozyme Therapeutics, Inc. | $8.1B | $68.55 | $88.25 | +28.7% | Buy | 8.5x | 27 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
 AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
 MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
 SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
 ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
PCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
What is the PCRX stock price target for 2026?
The consensus Wall Street price target for PCRX is $32, representing 43.3% upside from the current price of $22.33. With 36 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PCRX a buy, sell, or hold?
PCRX has a consensus rating of "Hold" based on 36 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $32 implies 43.3% upside from current levels.
Is PCRX stock overvalued or undervalued?
With a forward P/E of 7.7616x, PCRX trades at a relatively low valuation. The consensus target of $32 implies 43.3% appreciation, suggesting meaningful undervaluation.
How high can PCRX stock go?
The most bullish Wall Street analyst has a price target of $32 for PCRX, while the most conservative target is $32. The consensus of $32 represents the median expectation. Our quantitative valuation model projects a bull case target of $39 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover PCRX stock?
PCRX is heavily covered by Wall Street, with 36 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 17 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PCRX stock forecast?
The 12-month PCRX stock forecast based on 36 Wall Street analysts shows a consensus price target of $32, with estimates ranging from $32 (bear case) to $32 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $29, with bear/bull scenarios of $19/$39.
What is PCRX's fair value based on fundamentals?
Our quantitative valuation model calculates PCRX's fair value at $29 (base case), with a bear case of $19 and bull case of $39. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
What is PCRX's forward P/E ratio?
PCRX trades at a forward P/E ratio of 7.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 139.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PCRX stock?
Wall Street analysts are very optimistic on PCRX, with a "Hold" consensus rating and $32 price target (43.3% upside). 15 of 36 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PCRX price targets vary so much?
PCRX analyst price targets range from $32 to $32, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $32 consensus represents the middle ground. Our model's $19-$39 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare